Trial Profile
A PHASE III, Randomized, Open-Label, Comparative, Multi - Center Study to Assess the Safety and Efficacy of Prograf (Tacrolimus) and MR4 (Modified Release Tacrolimus) in de Novo Kidney Transplant Recipients.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Feb 2012
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 13 Aug 2008 New trial record.